Plain-English translation of NCT04538937 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research registry — a long-term database — that follows patients with eosinophil-related lung diseases. Researchers are studying several conditions where too many eosinophils (a type of immune cell) damage the lungs and airways. One focus is on patients switching to a newer, easier-to-use form of mepolizumab, a medication that helps control eosinophils. Another focus is on patients with Samter Triad, a condition combining asthma, nasal polyps, and reactions to certain pain medications.
Doctors don't fully understand why some people develop these eosinophil-related lung diseases or how to best tell them apart, since they can look similar. This medication shows promise for some patients, but researchers need to learn more about how it works and which patients benefit most. By collecting long-term information from patients, doctors hope to improve diagnosis and treatment options.
You likely qualify if…
You likely don't qualify if…
You would participate in a long-term observational study, meaning researchers track your health over time rather than giving you a new treatment. If you're switching to the newer form of mepolizumab, researchers will monitor how well it works and how easy it is to use at home. You'll have regular clinic visits where doctors assess your symptoms, lung function, and eosinophil levels. Some patients may have blood samples taken for additional study of eosinophil types. The study is designed to follow your disease course and treatment response prospectively (looking forward), so you may participate for months or years.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Austria